Historic milestone positions Nigeria as a leader in local healthcare production
Codix Group, a subsidiary of Colexa Biosensor Ltd, has received approval from the World Health Organisation (WHO) to package its Prequalified HIV Rapid Diagnostic Test (RDT) kits at its factory in Nigeria.
This groundbreaking achievement makes the Standard Q HIV 1/2 Ab 3-Line Test the first WHO Prequalified HIV RDT to be packaged in Africa, marking a historic advancement for the continent.
In a statement released on Wednesday, Codix Group celebrated the milestone as a significant step toward enhancing Nigeria’s healthcare production capabilities and improving access to life-saving diagnostics.
“This accomplishment reflects our dedication to strengthening Nigeria’s healthcare infrastructure and aligns with the President’s vision of boosting local manufacturing and innovation,” the statement read.
Advancing Local Healthcare
Since its commissioning in December 2023, Colexa Biosensor has garnered recognition from global health organizations, including WHO, Global Fund, UNITAID, FIND, and PEPFAR. The factory’s capacity is seen as a critical move to reduce reliance on imported medical products, enhance access to high-quality In-Vitro Diagnostics (IVDs), and support Nigeria’s healthcare value chain.
“This approval also opens doors for procurement opportunities by Nigeria and international donors, bolstering efforts to combat HIV both locally and globally,” Codix Group added.
Implications for Healthcare in Africa
The milestone is expected to attract further investment in local healthcare production and inspire other African nations to advance their healthcare manufacturing capabilities. Codix Group reaffirmed its commitment to elevating healthcare standards across Nigeria and beyond, signaling a brighter future for the industry in Africa.
Comments are closed.